Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MGMT testing always worth an emotion.
Hegi ME, Ichimura K. Hegi ME, et al. Neuro Oncol. 2021 Sep 1;23(9):1417-1418. doi: 10.1093/neuonc/noab163. Neuro Oncol. 2021. PMID: 34240215 Free PMC article. No abstract available.
The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence.
Lambiv WL, Vassallo I, Delorenzi M, Shay T, Diserens AC, Misra A, Feuerstein B, Murat A, Migliavacca E, Hamou MF, Sciuscio D, Burger R, Domany E, Stupp R, Hegi ME. Lambiv WL, et al. Among authors: hegi me. Neuro Oncol. 2011 Jul;13(7):736-47. doi: 10.1093/neuonc/nor036. Epub 2011 Jun 3. Neuro Oncol. 2011. PMID: 21642372 Free PMC article.
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.
Bady P, Sciuscio D, Diserens AC, Bloch J, van den Bent MJ, Marosi C, Dietrich PY, Weller M, Mariani L, Heppner FL, Mcdonald DR, Lacombe D, Stupp R, Delorenzi M, Hegi ME. Bady P, et al. Among authors: hegi me. Acta Neuropathol. 2012 Oct;124(4):547-60. doi: 10.1007/s00401-012-1016-2. Epub 2012 Jul 19. Acta Neuropathol. 2012. PMID: 22810491 Free PMC article.
MGMT testing--the challenges for biomarker-based glioma treatment.
Wick W, Weller M, van den Bent M, Sanson M, Weiler M, von Deimling A, Plass C, Hegi M, Platten M, Reifenberger G. Wick W, et al. Nat Rev Neurol. 2014 Jul;10(7):372-85. doi: 10.1038/nrneurol.2014.100. Epub 2014 Jun 10. Nat Rev Neurol. 2014. PMID: 24912512 Free article. Review.
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJ, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CY, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M; European Organisation for Research and Treatment of Cancer (EORTC); Canadian Brain Tumor Consortium; CENTRIC study team. Stupp R, et al. Among authors: hegi me. Lancet Oncol. 2014 Sep;15(10):1100-8. doi: 10.1016/S1470-2045(14)70379-1. Epub 2014 Aug 19. Lancet Oncol. 2014. PMID: 25163906 Free article. Clinical Trial.
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam DH, Mazurkiewicz M, Salacz M, Ashby L, Zagonel V, Depenni R, Perry JR, Hicking C, Picard M, Hegi ME, Lhermitte B, Reardon DA. Nabors LB, et al. Among authors: hegi me. Neuro Oncol. 2015 May;17(5):708-17. doi: 10.1093/neuonc/nou356. Epub 2015 Mar 11. Neuro Oncol. 2015. PMID: 25762461 Free PMC article. Clinical Trial.
157 results